Enzo Biochem (NYSE:ENZ) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of Enzo Biochem (NYSE:ENZ) in a research note issued to investors on Monday. The brokerage issued a hold rating on the medical research company’s stock.

Enzo Biochem Trading Down 3.6 %

Enzo Biochem stock opened at $0.58 on Monday. Enzo Biochem has a 12-month low of $0.58 and a 12-month high of $1.40. The firm has a 50 day simple moving average of $0.79 and a 200-day simple moving average of $1.00.

Enzo Biochem (NYSE:ENZ) last issued its quarterly earnings results on Monday, December 16th. The medical research company reported ($0.05) earnings per share (EPS) for the quarter. Enzo Biochem had a negative net margin of 75.34% and a negative return on equity of 7.96%.

Institutional Trading of Enzo Biochem

An institutional investor recently bought a new position in Enzo Biochem stock. BBR Partners LLC acquired a new position in shares of Enzo Biochem, Inc. (NYSE:ENZ) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 100,000 shares of the medical research company’s stock, valued at approximately $112,000. BBR Partners LLC owned 0.19% of Enzo Biochem at the end of the most recent quarter. 36.90% of the stock is owned by institutional investors and hedge funds.

Enzo Biochem Company Profile

Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.